The Impact of Adverse Events, Produced by Antibodies Conjugates, on Quality of Life in Patients With Metastatic Breast Cancer: Multicentric, Observational Study (EVA).

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

92 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-02

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study stems from the need to detect adverse events arising after the administration of Antibody-Drug Conjugates (ADCs) used in the treatment of metastatic breast cancer in a real life context and to correlate the same with the quality of life reported by patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation

NCT02860585

Breast Neoplasms

COMPLETED

Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy

NCT02403869

Breast Neoplasms

COMPLETED

Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer

NCT07021911

Breast Cancer Radiotherapy; Complications

RECRUITING

Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer

NCT00002544

Breast Cancer

COMPLETED PHASE3

Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

NCT06840483

Breast Cancer

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study stems from the need to detect adverse events arising after the administration of ADCs used in the treatment of metastatic breast cancer in a real life context and to correlate the same with the quality of life reported by patients.Through the findings of toxicities related to the ADCs, it will be possible to highlight which are the issues that most affect patients undergoing these cancer treatments. The analysis of the data collected will also make it possible to highlight any toxicities not yet considered or/and of new onset. In addition useful elements may emerge from responses to the quality of life questionnaire, to cope with the difficulties expressed by patients regarding daily life activities, social relations, work and family. Such contributions will be fundamental to the construction of integrated care pathways, the aim of which is to involve a specialized nurse as part of a multidisciplinary team.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female gender;
* Age ≥ 18 years;
* Signature of consent to participate in the study and to the processing of personal data (Privacy);
* Diagnosis of stage IV breast cancer;
* Systemic treatment with T-DM1, T-DXD or SG as monotherapy;
* Absence of cognitive decline, expressed by a score greater than or equal to 4 on the Six Item Screener questionnaire;
* Good understanding of the Italian language;
* Willingness and ability to adhere to scheduled visits, treatment plan, laboratory tests and study procedures.